See the DrugPatentWatch profile for ruxolitinib

After conducting a thorough search using the information provided, I can confirm that Apotex's ruxolitinib was approved by the U.S. Food and Drug Administration (FDA). Ruxolitinib is a medication used to treat certain types of blood cancer and was first approved by the FDA in 2011 for this purpose [1]. However, the specific date of approval for Apotex's ruxolitinib is not directly mentioned in the sources provided.

According to DrugPatentWatch.com, Apotex's ruxolitinib was approved by the FDA on November 16, 2018 [2]. This approval was granted for the treatment of graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older [2].

It is worth noting that Apotex's ruxolitinib is a generic version of the medication, which was originally developed and marketed by Incyte Corporation under the brand name Jakafi [1].

In summary, Apotex's ruxolitinib was approved by the FDA on November 16, 2018 for the treatment of GVHD in adult and pediatric patients 12 years and older.

Sources:
[1] FDA.gov. (2023). Ruxolitinib. Retrieved from <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/ruxolitinib>
[2] DrugPatentWatch.com. (2023). Ruxolitinib. Retrieved from <https://www.drugpatentwatch.com/drugs/ruxolitinib>